Arrowhead Pharmaceuticals, Inc.
82.63USD
-2.4800 (-2.91%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-1.54▼ | $-1.13 | 0 | 5 |
| Next quarter | $-1.34▲ | $-1.35 | 0 | 1 |
| Current year | $-3.54▼ | $-3 | 0 | 6 |
| Next year | $-4.8▼ | $-4.34 | 0 | 6 |
Beat in 2 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-1.23 | $-1.36 | -0.13 (-10.4%) |
| 2026-03-31 | $-1.11 | $-0.93 | +0.18 (+16.0%) |
| 2025-12-31 | $-0.37 | $0.22 | +0.59 (+159.9%) |
| 2025-09-30 | $-0.16 | $-0.18 | -0.02 (-14.5%) |
188 ratings from 25 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Citigroup | Initiated | Buy | $108 | Sep 8, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $120 | Sep 1, 2026 |
| Chardan Capital | Maintained | Buy | $115 | Aug 31, 2026 |
| RBC Capital | Reiterated | Outperform | $100 | Aug 31, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $115 $120 | Aug 6, 2026 |
| B. Riley Securities | Maintained | Buy | $101 $123 | Jul 30, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $100 $115 | Jul 27, 2026 |
| Morgan Stanley | Maintained | Overweight | $100 $120 | Jul 23, 2026 |
| Piper Sandler | Reiterated | Overweight | $110 $126 | Jul 23, 2026 |
| Chardan Capital | Maintained | Buy | $90 $115 | Jul 22, 2026 |
| JP Morgan | Maintained | Overweight | $88 $95 | Jul 17, 2026 |
| Stifel | Initiated | Buy | $98 | Jul 14, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $100 | Jul 1, 2026 |
| Chardan Capital | Maintained | Buy | $90 | Jun 30, 2026 |
| Leerink Partners | Maintained | Market Perform | $61 $72 | Jun 17, 2026 |
| Bernstein | Maintained | Market Perform | $35 $46 | May 13, 2026 |
| RBC Capital | Maintained | Outperform | $80 $87 | May 8, 2026 |
| JP Morgan | Initiated | Overweight | $88 | May 1, 2026 |
| Morgan Stanley | Upgraded from Equal-Weight | Overweight | $78 $100 | Apr 21, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $100 | Mar 25, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $100 | Feb 10, 2026 |
| B. Riley Securities | Maintained | Buy | $61 $101 | Jan 22, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $85 $100 | Jan 21, 2026 |
| Piper Sandler | Reiterated | Overweight | $100 $110 | Jan 13, 2026 |
| Goldman Sachs | Maintained | Neutral | $50 $85 | Jan 7, 2026 |
66 filings from 14 insiders · 1 buy / 6 sell over 6m
Officers and directors of ARWR, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| OLUKOTUN ADEOYE YDirector | Sell | 2.0k | $86.96 | $174k | Aug 18, 2026 |
| PERRY MICHAEL SDirector | Sell | 11.6k | $87.30 | $1.01M | Aug 18, 2026 |
| COHEN MATTHEW GREGORYDirector | Grant | 11.9k | — | — | Jun 15, 2026 |
| LU HONGBO BDirector | Sell | 3.0k | $76.88 | $228k | May 12, 2026 |
| HAMILTON JAMES COfficer | Sell | 10.0k | $75.00 | $750k | Apr 23, 2026 |
| APEL DANIEL JOSEPHChief Financial Officer | Sell | 13.1k | $70.11 | $934k | Apr 22, 2026 |
| HAMILTON JAMES COfficer | Sell | 10.0k | $64.19 | $642k | Mar 5, 2026 |
| O'BRIEN PATRICK CChief Operating Officer | Grant | 75.0k | — | — | Jan 6, 2026 |
| HAMILTON JAMES COfficer | Grant | 75.0k | — | — | Jan 6, 2026 |
| APEL DANIEL JOSEPHChief Financial Officer | Grant | 75.0k | — | — | Jan 6, 2026 |
| O'BRIEN PATRICK CChief Operating Officer | Gift | 2.5k | — | — | Jan 6, 2026 |
| HAMILTON JAMES COfficer | Sell | 40.2k | $61.24 | $2.53M | Jan 5, 2026 |
| O'BRIEN PATRICK CChief Operating Officer | Sell | 49.5k | $61.12 | $3.12M | Jan 5, 2026 |
| ANZALONE CHRISTOPHER RICHARDChief Executive Officer | Sell | 13.2k | $65.88 | $872k | Jan 2, 2026 |
| O'BRIEN PATRICK CChief Operating Officer | Gift | 2.8k | — | — | Dec 31, 2025 |
| ANZALONE CHRISTOPHER RICHARDChief Executive Officer | Exercise | 51.7k | $6.15 | $318k | Dec 29, 2025 |
| ANZALONE CHRISTOPHER RICHARDChief Executive Officer | Sell | 51.7k | $68.69 | $3.58M | Dec 29, 2025 |
| FERRARI MAURODirector | Sell | 7.5k | $70.00 | $527k | Dec 26, 2025 |
| ANZALONE CHRISTOPHER RICHARDChief Executive Officer | Sell | 26.0k | $66.67 | $1.77M | Dec 22, 2025 |
| OLUKOTUN ADEOYE YDirector | Sell | 10.0k | $66.70 | $677k | Dec 19, 2025 |
No analyst notes on ARWR yet.
Analyst Ratings
12 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 4 | 9 | 0 | 0 | 0 | Buy1.69 |
| 1 mo ago | 4 | 8 | 0 | 0 | 0 | Buy1.67 |
| 2 mo ago | 4 | 8 | 0 | 0 | 0 | Buy1.67 |
| 3 mo ago | 4 | 7 | 2 | 0 | 0 | Buy1.85 |